ARTICLE | Clinical News

Trajenta regulatory update

February 6, 2012 8:00 AM UTC

The Scottish Medicines Consortium recommended restricted the use of Trajenta linagliptin from Eli Lilly and Boehringer on the National Health Service (NHS) in Scotland to treat Type II diabetes. The consortium recommends the use of the product only in combination with metformin when diet and exercise plus metformin alone does not provide adequate glycemic control in patients for whom the addition of a sulphonylurea is inappropriate. The consortium said the manufacturer's submission related only to Trajenta's use in combination with metformin. ...